ProCE Banner Activity

IMPAACT 2010 Update: Comparable Safety and Efficacy With DTG + FTC/TAF or FTC/TDF vs EFV/FTC/TDF at 50 Wks Postpartum Following Initiation in Pregnancy

Slideset Download
Conference Coverage

In this randomized noninferiority trial, the overall safety and efficacy of DTG plus FTC/TAF or FTC/TDF was generally similar to EFV/FTC/TDF when initiated during pregnancy, but in post hoc analyses, infant mortality, virologic failure at ≥ 24 weeks, and maternal weight loss were all higher with EFV/FTC/TDF vs DTG-based regimens.

Released: March 11, 2021

Expiration: March 10, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Gilead

Janssen Therapeutics Division of Janssen Products

Merck Sharp & Dohme Corp.

ViiV Healthcare